(319) Multifunctional nanoparticles to fight hormone-resistant prostate cancer
Introduction: Prostate cancer is the second most diagnosed cancer in men (1). Androgen deprivation therapy, the standard treatment, leads to the development of castration-resistant prostate cancer (CRPC) in 10 to 20% of cases within five years (2,3). The emergence of such resistance can be partially explained by the overexpression of the specific cell membrane receptor HER2 (4). Therefore, we aim to target this receptor to develop nanomedicines to treat CRPC.
Learning Objectives:
Discuss the impact of MOFs PEGylation on the stability of MOFs and their interaction with cells.
Evaluate the impact of gemcitabine-monophosphate encapsulation in MOFs on the efficacy of the drug.
Determine the efficacy of the selected nanoformulation on an in vivo screening model.
